Evernic Acid
(Synonyms: 扁枝衣二酸,NSC 81164) 目录号 : GC13238
A FAS-II enzyme inhibitor
Cas No.:537-09-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Evernic Acid is an inhibitor of two key plasmodial FAS-II enzymes PfFabZ and PfFabI
The Type II fatty acid synthase (FAS) system catalysed fatty acid biosynthesis in most bacteria. Fatty acids are aliphatic acids important for energy production and storage, cellular structure and as intermediates in the biosynthesis of hormones and other biologically important molecules. The FAS-II exists in archaea and bacteria, which has been characterized by the use of discrete, monofunctional enzymes for fatty acid synthesis. Inhibitors of this pathway (FASII) are being investigated as possible antibiotics. The bacterial FASII pathway is a promising target for the development of novel antimicrobial drugs [2]. Disruption of genes encoding mitochondrial FAS enzymes in yeast results in a respiratory-deficient phenotype and small rudimentary mitochondria [3].
Evernic acid was a secondary metabolite produced by some species of lichen. Evernic acid bound to allosteric sites on the protein surface of FAS-II enzymes and produced antibacterial and antiplasmodial effects. Evernic acid inhibited PfFabZ and PfFabI with the IC50 values of 10.7 and 36.1 μM, respectively. Evernic acid showed low efficacy against the malaria parasite P. berghei with an IC50 of 77.3 μM [1].
References:
[1] Lauinger I L, Vivas L, Perozzo R, et al. Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target[J]. Journal of natural products, 2013, 76(6): 1064-1070.
[2] Marrakchi H, Zhang Y M, Rock C O. Mechanistic diversity and regulation of Type II fatty acid synthesis[J]. 2002.
[3] Hiltunen J K, Schonauer M S, Autio K J, et al. Mitochondrial fatty acid synthesis type II: more than just fatty acids[J]. Journal of Biological Chemistry, 2009, 284(14): 9011-9015.
| Cas No. | 537-09-7 | SDF | |
| 别名 | 扁枝衣二酸,NSC 81164 | ||
| 化学名 | 2-hydroxy-4-[(2-hydroxy-4-methoxy-6-methylbenzoyl)oxy]-6-methyl-benzoic acid | ||
| Canonical SMILES | CC1=CC(OC(C2=C(C)C=C(OC)C=C2O)=O)=CC(O)=C1C(O)=O | ||
| 分子式 | C17H16O7 | 分子量 | 332.3 |
| 溶解度 | ≤0.5mg/ml in ethanol;10mg/ml in DMSO;10mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0093 mL | 15.0466 mL | 30.0933 mL |
| 5 mM | 0.6019 mL | 3.0093 mL | 6.0187 mL |
| 10 mM | 0.3009 mL | 1.5047 mL | 3.0093 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。